Bili A, Dobson S, Quinones J, Phongsamart W, Oberdorfer P, Kosalaraksa P, Dagan R, Richmond P, Wilck M, Vallejos W, Nunn C, McFetridge R, Tamms G, Fu R, Lupinacci R, Musey L, Bickham K A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION) , Vaccine: 2023

Russell K, Rupp RE, Morales-Ramirez JO, Diaz-Perez C, Andrews AP, Lee AW, Finn TS, Cox KS, Russell AF, Schaller MM, Martin JC, Hyatt DM, Gozlan-Kelner S, Bili A, Coller BG. A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults , Human Vaccines and Immunotherapeutics : 2022

Aletaha D, Bingham CO, Karpouzas GA, Takeuchi T, Thorne C, Bili A, Agarwal P, Hsu B, Rao R, Brown K, Tanaka Y Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE) , RMD Open 2021 , 7: 2020,e001465

Schanberg LE, Ramanan AV, De Benedetti F, Beukelman T, Eakin GS, Del Gaizo V, Ringold S, Vesely R, Schrandt S, Jaki T, Bili A, Chung JB, De Bono S, Douglass W, Enejosa JV, Kanik KS, Knobe K, Kunder R, Leite-Schnell JC, Suehiro RM, Wong RL, Mieszkalski KL, Marrow LC, Siebenaler K, Fraulo E, Kimura Y. Toward Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis. Arthritis , Rheumatol , 71(12): 2019,1976-1984

Sharma T, Wasko MC, Tang X, Vedamurthy D, Yan X, Cote J, Bili A. Hydroxychloroquine use is Associated with Decreased Risk of Cardiovascular Events in Rheumatoid Arthritis Patients. , J Am Heart Assoc., 5(1): 2016,e002867

Schroeder LL, Tang X, Wasko MC, Bili A. Glucocorticoid use is associated with increased HDL in rheumatoid arthritis patients. , Rheumatol Int., 35(6): 2015,1059-67

Bili A, Tang X, Pranesh S, Bozaite R, Morris S, Antohe J, Kirchner HL. Wasko MC. TNF-α inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis patients. , Arthritis Care Res (Hoboken), 66(3): 2014,355-63

Cote J, Harrington TH, Meadows A, Lin F, Bili A Fellow’s Forum Case Report: New Sarcoidosis Cases in Patients Treated with Tumor Necrosis Factor–Alpha Inhibitors , The Rheumatologist: 2013

Cote J, Bili A Aspirin use in rheumatoid arthritis patients with increased risk of cardiovascular disease. , ISRN Rheumatology, 2013(589807): 2013

Bili A, Morris SJ, Sartorius JA, Kirchner HL, Antohe JA, Dancea S, Wasko MCM TNF-α inhibitor use is not associated with lipid changes in patients with rheumatoid arthritis. , J Rheumatol, 39(5): 2012,946-948